CENBinactive

CEN BIOTECH INC

Healthcare·Immunology
ImmunologyInfectious DiseaseRespiratoryDermatologyMusculoskeletal

CEN BIOTECH INC (CENB): 2 pipeline candidates · ~7 mo cash runway · 7 clinical trials. Updated within the last hour.

5.5/10

BioSniper Score

3-factor signal · derived from public data

Cash Runway1.8

6.5 months

Financial Health10.0

D/E -4.76 · 0% dilution

Pipeline MaturityN/A

N/A

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for CEN BIOTECH INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$148K

Quarterly Burn

$90K

Runway

6.5 mo

Revenue

$136K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jan 2027
Today~7 mo out
Catalyst within runway

Pipeline (2 candidates)

DrugPhase
follow-up period after dermocorticoid treatment alone—
treatment period with dermocorticoid alone—
7 clinical trials

Frequently asked questions

How many drug candidates are in CEN BIOTECH INC's pipeline?

CEN BIOTECH INC (CENB) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is CEN BIOTECH INC's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, CEN BIOTECH INC has approximately 6.5 months of cash runway.

Get the full picture on CEN BIOTECH INC

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar